ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

http://www.ecoanimalhealthgroupplc.com/

Half-yearly Report
BZW
Half-yearly Report

Eco Animal Health Group Plc


ECO Animal Health Group plc (ECO)

(AIM: EAH)

Results for the six months ended 30 September 2015

ECO ANIMAL HEALTH REPORTS STRONG PERFORMANCE

HIGHLIGHTS

Financials

27% increase in revenue to 21.5 million (2014:17.0 million), equivalent to a 28% increase at constant exchange rates (CER)
26% increase in adjusted EBITDA to 4.3 million (2014: 3.4 million), equivalent to a 36% increase at CER
33% increase in pre-tax profit to 2.7 million (2014: 2.0 million)
31% increase in earnings per share to 3.52 pence (2014:2.68 pence)
17% increase in gross profit to 8.9 million (2014: 7.6 million)
27% increase in interim dividend to 1.9 pence (2014:1.5 pence)
Cash generation again strong leaving net cash of 17.0 million (2014: 14.3 million)
Operations

Demand for Aivlosin continues to grow strongly with sales up over 32%, equivalent to 34% at CER
Strong performances in all major territories
EU approval of Maximum Residue Level for poultry eggs allowed submission of applications for new marketing authorisations
Continued investment in stockholding achieved and production capacity increase on schedule
Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:

"The second half of the year has started well continuing the momentum of the first six months. ECO is in excellent financial and commercial health and we look forward with confidence to delivering another strong set of results, backed by further penetration of key markets and the achievement of additional marketing authorisations."

7 Dec Peel Hunt 350.00 Buy

Regulatory Approval

BUS


Regulatory Approval

Eco Animal Health Group Plc



31 March 2016

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES MARKETING AUTHORISATION

FOR AIVLOSIN IN THE USA

ECO is pleased to announce that it has been granted a marketing authorisation for Aivlosin in the United States by the Center for Veterinary Medicine (CVM) of the Food and Drug Administration (FDA).

Aivlosin, ECOs patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

This authorisation is for a Type A Medicated Article (Premix) formulation for the treatment of ileitis (porcine proliferative enteropathy (PPE)), an enteric disease of swine. This new treatment meets all the guidelines for the responsible use of antimicrobials. Importantly, with global concerns about the use of antibiotics in food production animals, this treatment is under the control of veterinarians and has a low, highly effective therapeutic dose rate, short treatment duration and zero day drug withholding period.

This approval in the United States follows the recent successful Canadian launch of this formulation and marks a very important step in the Companys continuing development of Aivlosin as a global veterinary product. The product will be marketed through Pharmgate Animal Health LLC our well-established sales and marketing joint venture formed in 2010 with Pharmgate LLC, the majority-owned U.S. subsidiary of Jinhe Biotechnology Co. Ltd. in China.

Peter Lawrence, Chairman of ECO commented We are delighted to receive this marketing authorisation in the United States. This key milestone follows many years of investment in product development and regulatory activity in North America. The USA represents more than one third of the world market for our products and this breakthrough will benefit our future profitable growth. It underlines ECOs continued commitment to being a major force in the international market for veterinary pharmaceutical products.

Broker Forecast - Peel Hunt issues a broker note on Eco Animal Health Group PLC

Peel Hunt today reaffirms its buy investment rating on Eco Animal Health Group PLC (LON:EAH) and raised its price target to 375p (from 350p). Story provided by StockMarketWire.com

Regulatory Approval

BUS


Regulatory Approval

Eco Animal Health Group Plc



22 April 2016

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES POSITIVE OPINION ON AIVLOSIN FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION FOR THE EU

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) for the use of Aivlosin 625 mg/g water soluble granules in chickens laying eggs for human consumption.

This positive opinion will allow for the medication of drinking water with Aivlosin for the treatment of respiratory infection caused by Mycoplasma gallisepticum in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.

ECO is now able to accelerate the submission of the Aivlosin regulatory files for the treatment of layers in its key global markets.

Aivlosin, ECOs patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Peter Lawrence, Chairman of ECO, commented This positive opinion from the European regulatory authorities for commercial layers is another encouraging and positive step in the development of Aivlosin as a fast growing, truly global brand. It underlines ECOs continued commitment to being a major force in the international market for veterinary pharmaceutical products.

Regulatory Approval

BUS


Regulatory Approval

Eco Animal Health Group Plc



03 June 2016

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the European Medicines Agency (EMA) for the use of Aivlosin 625 mg/g water soluble granules in chickens laying eggs for human consumption.

This approval will allow ECO to start selling Aivlosin for the medication of drinking water for the treatment of respiratory infection caused by Mycoplasma gallisepticum in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.

Aivlosin, ECOs patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Peter Lawrence, Chairman of ECO, commented This approval from the European regulatory authorities is an important step in the development of Aivlosin for commercial layers. ECO is now able to accelerate the submission of the Aivlosin regulatory files for the treatment of layers in the key global egg producing markets. It underlines ECOs continued commitment to being a major force in the international market for veterinary pharmaceutical products.

Contacts:

ECO Animal Health Group plc Peter Lawrence 020 8336 6190

Marc Loomes 020 8447 8899

Spiro Financial Anthony Spiro 020 8336 6196

Peel Hunt LLP Dan Webster 020 7418 8900

(Nominated Adviser) Adrian Trimmings 020 7418 8900

George Sellar 020 7418 8900

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders

Final Results

BUS


Final Results

Eco Animal Health Group Plc



ECO Animal Health Group plc (ECO)

(AIM: EAH)

Results for the year ended 31 March 2016

ECO ANIMAL HEALTH REPORTS ANOTHER STRONG PERFORMANCE

HIGHLIGHTS

Financials
• 51% increase in pre tax profit to 7.7m (2015: 5.1m)
• 21% increase in sales to 47.1m (2015: 39.0m)
• 21% increase in gross profit to 21.0m (2015: 17.5m) maintaining margin
• 29% increase in adjusted EBITDA to 11.1m (2015: 8.6m)
• 27% increase in second interim dividend to 3.80p (2015: 3.0p) making total dividend for the
• year up 20% to 5.7p (2015:4.75p)
• Strong cash generation from operations
• Net cash of 16.0 million at year end

Operations
• Demand for Aivlosin continues to grow strongly with sales up 22%
• New marketing authorisations gained in USA and Europe (post period end)
• Strong performances in all major geographic areas
• Continued investment in product development and stockholding to support growth

Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:

The new financial year has started well with sales maintaining momentum. The recent weakness in the value of sterling may benefit ECO as virtually all our sales and majority of costs arise locally in dollars, RMB or the euro. Our newly gained approvals for Aivlosin should provide another platform for future growth and I look forward with confidence to ECO delivering another impressive performance.

Broker Forecast - Peel Hunt issues a broker note on Eco Animal Health Group PLC

BFN

Peel Hunt today reaffirms its buy investment rating on Eco Animal Health Group PLC (LON:EAH) and raised its price target to 450p (from 375p).

Story provided by StockMarketWire.com

Ex divi -

Eco Animal Health Group PLC [EAH] (3.8p

AGM Statement

BUS


AGM Statement

Eco Animal Health Group Plc



AGM Trading Statement

ECO Animal Health Group plc

(ECO or the Company)

16 September 2016

At the Companys annual general meeting this morning, Peter Lawrence, the Chairman, will make the following statement:

Trading this year has started well and the first five months saw sales significantly ahead of the same period last year. Following the Brexit vote last June and the weakening of sterling against the major currencies in which we invoice ca 97% of sales, it is anticipated that some foreign exchange benefits will enhance earnings. I look forward to reporting interim results to 30 September in December.

Regulatory Approval
BUS
Regulatory Approval



Eco Animal Health Group Plc

19 October 2016
ECO Animal Health Group plc
(AIM: EAH)
ECO RECEIVES FIRST NON-EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the Thailand Food and Drug Administration (FDA) for the use of Aivlosin 625 mg/g water soluble granules in chickens laying eggs for human consumption.
This approval, the first following the European approval in June, will allow ECO to start selling Aivlosin in Thailand for the medication of drinking water for the treatment of respiratory infection caused by Mycoplasma gallisepticum in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.
Aivlosin, ECOs patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
Peter Lawrence, Chairman of ECO, commented This approval from the Thai FDA is an important step in the development of Aivlosin for commercial layers with Thailand being ranked as a global top twenty egg producing country. ECO has begun the process of submitting the Aivlosin regulatory files for the treatment of layers in numerous other key egg producing markets. It underlines ECOs continued commitment to being a major force in the international market for veterinary pharmaceutical products.

Regulatory Approval
BUS
Regulatory Approval
Eco Animal Health Group Plc

ECO Animal Health Group plc
(AIM: EAH)
ECO RECEIVES BRAZILIAN MARKETING AUTHORISATION FOR AIVLOSIN WATER SOLUBLE GRANULES FOR SWINE
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health do Brasil, has received a marketing authorisation from the Brazilian Ministry of Agriculture, Livestock and Supply (MAPA) for the use of Aivlosin 625 mg/g water soluble granules in swine.
Aivlosin, ECOs patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
This formulation of Aivlosin will be marketed for the treatment of ileitis (porcine proliferative enteropathy (PPE)), an enteric disease of swine. Aivlosin water soluble granules dissolve readily in water providing a simple solution for the accurate and simultaneous treatment of large numbers of animals. Importantly, with global concerns about the use of antibiotics in production animals, this new treatment with its low therapeutic dose rate and short treatment duration meets antimicrobial stewardship guidelines.
Peter Lawrence, Chairman of ECO, commented This approval from the Brazilian MAPA is very important in the development of Aivlosin for swine globally. Brazil is one of the worlds leading producers and exporters of pork and this new formulation will enhance our ability to offer an expanded range of valuable therapeutic tools to swine producers for both the domestic and export markets .

5 Dec
N+1 Singer
N/A
Corporate
5 Dec
Peel Hunt
550.00
Buy

Half-year Report
BUS
Half-year Report
Eco Animal Health Group Plc

12 December 2016
ECO Animal Health Group plc ("ECO")
(AIM: EAH)
Results for the six months ended 30 September 2016
ECO ANIMAL HEALTH REPORTS STRONG PERFORMANCE
HIGHLIGHTS
Financials
25% increase in revenue to 26.9 million (2015: 21.5 million)
43% increase in gross profit to 12.8 million (2015: 8.9 million)
46% increase in adjusted EBITDA to 6.3 million (2015: 4.3 million)
97% increase in pre-tax profit to 5.3 million (2015: 2.7 million)
61% increase in earnings per share to 5.68 pence (2015:3.52 pence)
32% increase in interim dividend to 2.5 pence (2015: 1.9 pence)
Cash generation again strong leaving net cash of 18.5 million (2015: 17.0 million)
Operations
Demand for Aivlosin continues to grow strongly with sales up over 15%
Strong performances in the USA and China
EU Aivlosin approval for commercial layers with a zero withdrawal period for eggs allowed submission of regulatory files to key global egg producing markets ; Thailand approval received post period end
Continued investment in stockholding achieved
Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:
The second half of the year has started well with strong order books. ECO has a sound balance sheet and cash flow generation. The company continues to invest successfully in its research and product development programme to obtain further marketing authorisations. I look forward with confidence to reporting another set of strong results in 2017.

12 Dec
Peel Hunt
575.00
Buy
12 Dec
N+1 Singer
N/A
Corporate

Regulatory Approval
BUS
Regulatory Approval
Eco Animal Health Group Plc

9 January 2017
ECO Animal Health Group plc
(AIM: EAH)
ECO RECEIVES MEXICAN MARKETING AUTHORISATION FOR AIVLOSIN FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health de Mxico has received a marketing authorisation from the Secretariat of Agriculture, Livestock, Rural Development, Fisheries and Food (SAGARPA) of the Government of Mexico for the use of Aivlosin 625 mg/g water soluble granules in chickens laying eggs for human consumption.
This approval, the first in Latin America following the European approval in June 2016, will allow ECO to start selling Aivlosin in Mexico for the medication of drinking water for the treatment of infections caused by Mycoplasma in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.
Aivlosin, ECOs patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
Peter Lawrence, Chairman of ECO, commented This approval from the Mexican authorities is an important step in the development of Aivlosin for commercial layers with Mexico being the worlds fourth largest egg producing country. ECO has begun the process of submitting the Aivlosin regulatory files for the treatment of layers in numerous other key egg producing markets. It underlines ECOs continued commitment to being a major force in the international market for veterinary pharmaceutical products

9 Jan
Peel Hunt
575.00
Buy
9 Jan
N+1 Singer
N/A
Corporate

Holding(s) company >14%

Trading Statement
BUS
Trading Statement
Eco Animal Health Group Plc

Eco Animal Health Group plc (the "Group")
Trading statement
ECO Animal Health Group plc, the international producer of animal health pharmaceuticals, is releasing a trading statement in relation to its results for the year ended 31 March 2017.
The Group is likely to exceed the market expectations for revenue and significantly exceed the market expectations for pre-tax profit for the year ended 31 March 2017.
The announcement of the full results for the year to 31 March 2017 is anticipated to be released on 30 June 2017.

09:10 15/05/2017
Broker Forecast - Peel Hunt issues a broker note on Eco Animal Health Group PLC
Peel Hunt today reaffirms its buy investment rating on Eco Animal Health Group PLC (LON:EAH) and raised its price target to 650p (from 575p). Story provided by StockMarketWire.com

Final Results
BUS
Final Results
Eco Animal Health Group Plc


30 June 2017
ECO Animal Health Group plc (ECO)
(AIM: EAH)
Results for the year ended 31 March 2017
ECO ANIMAL HEALTH REPORTS ANOTHER STRONG PERFORMANCE
HIGHLIGHTS
Financials
30% increase in sales to 61.4m (2016: 47.1m)
44% increase in gross profit to 30m (2016: 21.0m) on improved margin
75% increase in pre-tax profit to 13.5m (2016: 7.7m)
54% increase in adjusted EBITDA to 17.1m (2016: 11.1m)
21% increase in second interim dividend to 4.6p (2016: 3.8p) making total dividend for the year up 25% to 7.1p (2016: 5.7p)
Strong cash generation from operations leaving net cash of 21.0 million at year end
Operations
Demand for Aivlosin continues to grow strongly
Strong performances in all major geographic areas, bar Brazil
New marketing authorisations gained in Europe, Brazil, Mexico and Thailand
Continued investment in new routes to market, product development, people and stockholding to support future growth
Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:
ECO has started the current year strongly with revenue ahead of the previous year. The ongoing weakness in the value of sterling may continue to be of benefit to ECO as virtually all our sales and the majority of costs arise locally in dollars, RMB or the euro. The business is robust with a sound, debt free balance sheet and this coupled with our strong cash generation will allow us to capitalise on market opportunities as they arise. We look forward with confidence.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations.

10:40 30/06/2017
Broker Forecast - Peel Hunt issues a broker note on Eco Animal Health Group PLC
Peel Hunt today reaffirms its buy investment rating on Eco Animal Health Group PLC (LON:EAH) and raised its price target to 725p (from 650p). Story provided by StockMarketWire.com

ECO gets US regulatory approval for Aivlosin
StockMarketWire.com
ECO Animal Health Group's subsidiary ECO Animal Health Limited has received a marketing authorisation for Aivlosin in the United States from the Center for Veterinary Medicine of the Food and Drug Administration.

Aivlosin, ECO's patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

ECO said this authorisation was for the use of Aivlosin 625 mg/g water soluble granules in for the control of swine respiratory disease (SRD) associated with Bordetella bronchiseptica, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis, four important bacterial respiratory pathogens of swine.

ECO said: "This new treatment meets all the guidelines for the responsible use of antimicrobials. Importantly, with global concerns about the use of antibiotics in food production animals, this treatment is under the control of veterinarians, is available under prescription only and has a low, highly effective therapeutic dose rate, short treatment duration and a zero day drug withholding period."

ECO aid the product would be marketed through Pharmgate Animal Health LLC, the group's well-established sales and marketing joint venture formed in 2010 with Pharmgate LLC, the majority-owned US subsidiary of Jinhe Biotechnology Co. Ltd. in China.

ECO chairman Peter Lawrence said: "We are extremely pleased to receive this second marketing authorisation for the Aivlosin water soluble granules formulation in the United States.

"The swine respiratory disease segment is a key one and this latest approval demonstrates ECOs continued progress to becoming a major force in the international market for veterinary pharmaceutical products."



Story provided by StockMarketWire.com

Regulatory Approval
BUS
Regulatory Approval
Eco Animal Health Group Plc

ECO Animal Health Group plc
(AIM: EAH)
ECO RECEIVES CANADIAN MARKETING AUTHORISATION FOR AIVLOSIN FOR SWINE RESPIRATORY DISEASE
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation for Aivlosin in Canada from the Veterinary Drugs Directorate of Health Canada.
Aivlosin, ECOs patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.
This authorisation is for the use of Aivlosin 625 mg/g water soluble granules for swine respiratory disease (SRD) associated with Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis, three important bacterial respiratory pathogens of swine.
This new treatment meets all the guidelines for the responsible use of antimicrobials. Importantly, with global concerns about the use of antibiotics in food production animals, this treatment is under the control of veterinarians, is available under prescription only and has a low, highly effective therapeutic dose rate, short treatment duration and a zero day drug withholding period.
The product will be marketed through Pharmgate Animal Health Canada Inc. our well-established sales and marketing joint venture formed in 2010 with Pharmgate LLC, the majority-owned U.S. subsidiary of Jinhe Biotechnology Co. Ltd. in China.
Peter Lawrence, Chairman of ECO, commented We are extremely pleased to receive this second marketing authorisation for the Aivlosin water soluble granules formulation in Canada, the seventh largest pork producing country in the world. The swine respiratory disease segment is a key one and this latest approval demonstrates ECOs continued progress to becoming a major force in the international market for veterinary pharmaceutical products.

Recovery underway?